Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
- 1 July 1999
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 117 (1), 58-64
- https://doi.org/10.1016/s0016-5085(99)70550-0
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- MITIGATING EFFECTS OF INTERLEUKIN 11 ON CONSECUTIVE COURSES OF 5-FLUOROURACIL-INDUCED ULCERATIVE MUCOSITIS IN HAMSTERSCytokine, 1997
- Protection of the Small Intestinal Clonogenic Stem Cells from Radiation‐Induced Damage by Pretreatment with Interleukin 11 also Increases Murine Survival TimeThe International Journal of Cell Cloning, 1996
- The biology of interleukin 11The International Journal of Cell Cloning, 1996
- Effects of IL‐11 on the growth of intestinal epithelial cells in vitroCell Proliferation, 1995
- Dose response and schedule studies of recombinant human interleukin-11 in acetic acid-induced colonic injury in rats: L.M. Albert, T.J. Ferranti, J.E. Erickson, L.H. Donnelly, R.G. Schaub,Gastroenterology, 1995
- Recombinant human interleukin-11 (rhlL-11) decreases inflammatory bowel disease in HLA-B27 transgenic rats:Gastroenterology, 1995
- Interleukin (IL)-10 Inhibits Nuclear Factor кB (NFкB) Activation in Human MonocytesJournal of Biological Chemistry, 1995
- Immunosuppressive and Anti-inflammatory Properties of Interleukin 10Annals of Medicine, 1995
- Vascular Complications of Inflammatory Bowel DiseaseMayo Clinic Proceedings, 1986
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980